ba0002p83 | (1) | ICCBH2013
Schoen Pieter
, Jacobs Sandy
, Verschueren Katrien
, Ottevaere Ingrid
, Sobry Sigrid
, Holz Josefin-Beate
Objectives: The interaction between RANK and its ligand RANKL is critical for the regulation of osteoclastogenesis and bone resorption. Inhibition of this interaction helps restore the balance between bone resorption and bone formation. ALX-0141, a novel biological agent (Nanobody) that specifically targets RANKL, was studied in a phase I trial to assess the safety, tolerability, immunogenicity and PK after a single s.c. injection.Methods: Forty-two heal...